1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome
Clinical Research. Presentation type: Poster Presentation. Introduction: Empagliflozin is a potent and selective SGLT2-I used in the treatment of T2DM. Methodology: Study design: Patients with T2DM and established CV disease, and estimated glomerular filtration rate (eGFR;) ⩾30 ml/min/1.73 m2 were r...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Saudi Heart Association
2017-10-01
|
| Series: | Journal of the Saudi Heart Association |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S101673151730088X |